W/O & LC
Dispersed Systems
Industrialized nanoemulsions, reverse emulsions and liquid-crystal matrices
Technology Stack · Industrial Delivery Systems
Delivery Technology for Brands That Need Proof, Not Promises.
Delivery approaches are assessed against the product brief, ingredient properties, stability, evidence requirements and manufacturing constraints.
NATIVE
Native Collagen
Proprietary fish-derived native collagen and telopeptide-reduced atelocollagen
EXTERNAL LABS
EVIDENTIARY ANALYSIS
Analytical strategy designed by Olympia; evidentiary testing commissioned from independent qualified laboratories as required by the project.
Project scope
Scale Reliability
Product-specific process capability validation for enterprise transfer
What is supplement encapsulation?
Supplement encapsulation places an ingredient or ingredient system within a carrier or delivery structure so it can be incorporated into the intended product format. The suitable approach depends on ingredient properties and stability, the intended delivery or release behaviour, dose and format, market requirements and manufacturing constraints. It is a product-specific technical decision, not a guarantee of bioavailability, stability, efficacy or regulatory acceptance.
The Velvet Rope
Selective Admission for High-Impact Technology Mandates.
Technology options are scoped to the product brief, evidence requirements and agreed manufacturing constraints.
- You need a defensible delivery-system moat, not generic formulation mimicry.
- You require board-level technical evidence for valuation, clinic trust, or strategic exit.
- Your team is ready for disciplined validation, analytical release, and compliance governance.
- You are prepared to enter through Initiate R&D Due Diligence (paid).
Technology Protocol
Delivery Performance Must Survive Manufacturing Physics.
Our protocol aligns formulation intent with production reality. We define a product-specific technical rationale, analytical strategy and manufacturing controls before a delivery system is carried into scale-up.
Dispersed Systems
Product-specific delivery approaches scoped to the brief
Proprietary Collagen
Fish-derived native collagen and telopeptide-reduced atelocollagen
Barrier & Enteric
pH-targeted release and engineered moisture/oxygen barrier packaging
External Verification
Independent evidentiary testing strategy designed by Olympia Biosciences™ and commissioned from qualified external laboratories as required by the project.
Admission Outcomes
What Qualified Technology Admission Delivers.
A delivery-system decision tree anchored in evidence and manufacturability.
Analytical and process controls prepared for QA, regulator, and investor scrutiny.
A contract-governed route for scale-up, continuity and the agreed project deliverables.
Execution Ladder
Four Moves from Delivery Thesis to Enterprise Reliability.
01
Technical Diligence
Molecular and delivery-route triage with go/no-go decision logic.
02
Architecture Design
Delivery-system and process controls designed for repeatable output.
03
Validation Runs
Analytical and process verification before high-volume campaign activation.
04
Scale Transfer
Industrial execution with traceable governance and transfer-ready records.
Final Gate
Initiate R&D Due Diligence.
If your objective is category-defining delivery performance with defensible evidence, we can evaluate fit. If your objective is generic quote shopping, admission is intentionally closed.
Analytical release is defined in the product specification and agreed scope.
RELATED INTELLIGENCE
Global CDMO PortfolioPIS-registered production establishment in Gdynia, Poland (ul. Polska 20), public records and the operating principles behind technology mandatesEXPLORE ›Softgel Manufacturing: Fill–Shell CompatibilityProduct-specific feasibility for liquid and semi-solid fills, shell systems and stability evidenceEXPLORE ›Production FormatsFormat selection, scoped feasibility and commercial planning for the intended product pathwayEXPLORE ›Physician-Led Supplement CDMOClinician-led programmes evaluated through Paid Discovery and contract-defined deliverablesEXPLORE ›FSMP & Medical NutritionMedical-nutrition programmes scoped to the product category, evidence needs and applicable regulatory routeEXPLORE ›Scale-Up & TransferProduct-specific validation, governance and handover planning for commercial executionEXPLORE ›R&D HubScientific context for formulation and delivery-system decisionsEXPLORE ›Science-First ManifestoThe operating doctrine for evidence, manufacturability and responsible technical decisionsEXPLORE ›
Frequently Asked Questions
Why gate technology projects with paid due diligence?
Because advanced delivery work is execution-critical. We evaluate molecular fit, process risk, and validation feasibility before admission. Paid diligence filters speculative briefs and protects active partner programs.
What is assessed in the technology admission phase?
We assess ingredient physicochemistry, delivery-system compatibility, interaction risk, analytical strategy, and industrial transfer constraints. The outcome is a go/no-go decision with technical route definition.
Which delivery systems can be assessed in one program?
Project-specific formulation, evidence, quality and manufacturing requirements are defined in the agreed scope.
How do you prevent over-promising in bioavailability claims?
We use analytical and formulation evidence boundaries. Claims are framed from measurable outputs, not marketing assumptions. Programs without defensible data are not admitted to production route design.
How does Olympia approach fill-shell compatibility, e.g. for essential oils?
A quotation is not a feasibility assessment. Volatile essential-oil constituents can create fill-shell compatibility risks such as migration, plasticization or leakage. We assess the fill, shell polymer, seal, any enteric coating, packaging and stability evidence before confirming capsule feasibility.
Can enterprise auditors review your technology controls?
Qualified teams can review the project-specific evidence boundary, analytical strategy and relevant documentation during the agreed diligence scope.
Who owns the resulting formulation intelligence?
Rights to contracted project deliverables are defined in signed agreements.
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ is responsible for market-specific regulatory compliance, health claim authorisation, labelling and marketing of its finished product, as defined by the applicable agreement.